Shannon N. Westin
Member of Scientific Advisory BoardDr. Shannon N. Westin, M.D., MPH, is Member of Scientific Advisory Board of Nuvectis Pharma, Inc. from September 2022. Dr. Westin has experience as Director of Early Drug Development and Phase I Trials and has worked in Department of Gynecologic Oncology and Reproductive Medicine and The University of Texas, MD Anderson Cancer Center. Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She is a Co-Director of the Ovarian Cancer Moonshot program. She is the co-PI for major projects in her institution’s Specialized Programs of Research Excellence (“SPORE”) in Uterine Cancer and SPORE in Ovarian Cancer. At her institution, she is the Principal Investigator or co-Principal-Investigator for several novel treatment trials in gynecologic malignancies. In addition to previously serving on the National Cancer Institute (“NCI”) Uterine Task Force and Gynecologic Cancer Steering Committee (“GCSC”), she serves as a co-Chair of the GCSC Ovarian Cancer Task Force and on the Board of Directors of the Society of Gynecology Oncology and Gynecologic Oncology Group Foundation.
公司职务
- 公司名称Nuvectis Pharma, Inc.股票代码NVCT职务Member of Scientific Advisory Board共事同僚
- RBRon BentsurCo-Founder, Chairman, CEO & President
- EPEnrique PoradosuCo-Founder, Executive VP, Chief Scientific & Business Officer
- SSShay ShemeshCo-Founder, Executive VP, Chief Development & Operations Officer
- MCMichael CarsonVice President of Finance
- KHKenneth HobermanIndependent Director
- JFJames F. OlivieroIndependent Director
- MLMatthew Lee KaplanIndependent Director
